JP6902195B2 - 多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用 - Google Patents

多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用 Download PDF

Info

Publication number
JP6902195B2
JP6902195B2 JP2017564597A JP2017564597A JP6902195B2 JP 6902195 B2 JP6902195 B2 JP 6902195B2 JP 2017564597 A JP2017564597 A JP 2017564597A JP 2017564597 A JP2017564597 A JP 2017564597A JP 6902195 B2 JP6902195 B2 JP 6902195B2
Authority
JP
Japan
Prior art keywords
hrv
inactivated
serotypes
vaccine
vaccine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017564597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517722A (ja
JP2018517722A5 (enExample
Inventor
エル． ムーア，マーティン
エル． ムーア，マーティン
リー，スジン
チャン グェン，ミン
チャン グェン，ミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Healthcare of Atlanta Inc
Original Assignee
Childrens Healthcare of Atlanta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Healthcare of Atlanta Inc filed Critical Childrens Healthcare of Atlanta Inc
Publication of JP2018517722A publication Critical patent/JP2018517722A/ja
Publication of JP2018517722A5 publication Critical patent/JP2018517722A5/ja
Priority to JP2021088164A priority Critical patent/JP2021152024A/ja
Application granted granted Critical
Publication of JP6902195B2 publication Critical patent/JP6902195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017564597A 2015-06-15 2016-06-15 多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用 Active JP6902195B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021088164A JP2021152024A (ja) 2015-06-15 2021-05-26 多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562175832P 2015-06-15 2015-06-15
US62/175,832 2015-06-15
PCT/US2016/037658 WO2016205389A1 (en) 2015-06-15 2016-06-15 Multivalent enterovirus vaccine compositions and uses related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021088164A Division JP2021152024A (ja) 2015-06-15 2021-05-26 多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用

Publications (3)

Publication Number Publication Date
JP2018517722A JP2018517722A (ja) 2018-07-05
JP2018517722A5 JP2018517722A5 (enExample) 2019-07-18
JP6902195B2 true JP6902195B2 (ja) 2021-07-14

Family

ID=57546427

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017564597A Active JP6902195B2 (ja) 2015-06-15 2016-06-15 多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用
JP2021088164A Pending JP2021152024A (ja) 2015-06-15 2021-05-26 多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021088164A Pending JP2021152024A (ja) 2015-06-15 2021-05-26 多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用

Country Status (7)

Country Link
US (1) US11160857B2 (enExample)
EP (1) EP3307311A4 (enExample)
JP (2) JP6902195B2 (enExample)
KR (1) KR20180086180A (enExample)
CN (1) CN108025055B (enExample)
CA (1) CA2989332A1 (enExample)
WO (1) WO2016205389A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021152024A (ja) * 2015-06-15 2021-09-30 エモリー ユニバーシティー 多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109337876A (zh) * 2018-10-15 2019-02-15 北京世纪元亨动物防疫技术有限公司 一种猪流行性腹泻病毒的纯化方法
JP2022521410A (ja) * 2019-02-21 2022-04-07 センティヴァックス， インコーポレイテッド 最適化されたワクチン組成物およびその製造方法
CN115869324B (zh) * 2022-12-30 2024-02-27 湖北工业大学 Efavirenz在制备抗肠道病毒药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946676A (en) 1986-08-27 1990-08-07 De Staat Der Nederlanden Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide
US5714374A (en) 1990-09-12 1998-02-03 Rutgers University Chimeric rhinoviruses
US20020086386A1 (en) 1997-03-04 2002-07-04 Kamb Carl Alexander B-catenin assays, and compositions therefrom
US20060088549A1 (en) 2004-07-08 2006-04-27 Arnold Gail F Chimeric virus vaccine
US8153760B2 (en) 2005-01-19 2012-04-10 Donald Danforth Plant Science Center Rhinovirus vaccines
EP2066343B1 (en) * 2006-09-29 2017-06-14 Sanofi Pasteur Biologics, LLC Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications
US20110091501A1 (en) 2008-03-27 2011-04-21 Sanofi Pasteur Biologics Co. Recombinant Rhinovirus Vectors
EP2414520A2 (en) * 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
US20110293700A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EP2765137A1 (en) 2013-02-07 2014-08-13 Sanofi Pasteur Induction of cross-reactive cellular response against rhinovirus antigens
BR112015031541A2 (pt) * 2013-06-17 2017-07-25 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport métodos para o impedimento da agregação de componentes virais
WO2015179979A1 (en) 2014-05-28 2015-12-03 National Health Research Institutes Viral particles as immunogens against enterovirus infection and production thereof
US11160857B2 (en) * 2015-06-15 2021-11-02 Emory University Multivalent enterovirus vaccine compositions and uses related thereto

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021152024A (ja) * 2015-06-15 2021-09-30 エモリー ユニバーシティー 多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用

Also Published As

Publication number Publication date
CN108025055A (zh) 2018-05-11
EP3307311A4 (en) 2019-02-13
CA2989332A1 (en) 2016-12-22
JP2021152024A (ja) 2021-09-30
KR20180086180A (ko) 2018-07-30
US11160857B2 (en) 2021-11-02
JP2018517722A (ja) 2018-07-05
WO2016205389A1 (en) 2016-12-22
EP3307311A1 (en) 2018-04-18
US20180169215A1 (en) 2018-06-21
CN108025055B (zh) 2022-08-26

Similar Documents

Publication Publication Date Title
JP7239948B2 (ja) サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2021152024A (ja) 多価エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）ワクチン組成物およびそれに関連する使用
JP5933565B2 (ja) 組み換え改変ワクシニアウイルスアンカラインフルエンザワクチン
CN108602858A (zh) 嵌合rsv、免疫原性组合物以及使用方法
JP2022523157A (ja) キメラ型ＲＳＶおよびｈＭＰＶ Ｆタンパク質、免疫原性組成物、ならびに使用方法
JP2019520338A (ja) ウマインフルエンザウイルス弱毒生ワクチン
US12053518B2 (en) Method for rescuing and producing a virus in avian cells
US20220023413A1 (en) Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
US20240082385A1 (en) Rsv vaccines and methods of administering same
CN101993498A (zh) 腺病毒载体禽流感重组疫苗
CN119432910A (zh) 用于疫苗制备的重组质粒及其制备方法和dna启动的减毒活手足口病疫苗
CN119317446A (zh) 用于预防covid-19的重组新城疫病毒和免疫原性组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210526

R150 Certificate of patent or registration of utility model

Ref document number: 6902195

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250